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 Abstract 
 Europe has the highest proportion of elderly people in the world. Cardiovascular disease, type 
2 diabetes, sarcopenia and cognitive decline frequently coexist in the same aged individual, 
sharing common early risk factors and being mutually reinforcing. Among conditions which 
may contribute to establish early risk factors, this review focuses on maternal obesity, since 
the epidemic of obesity involves an ever growing number of women of reproductive age and 
children, calling for appropriate studies to understand the consequences of maternal obesity 
on the offspring’s health and for developing effective measures and policies to improve peo-
ple’s health before their conception and birth. Though the current knowledge suggests that 
the long-term impact of maternal obesity on the offspring’s health may be substantial, the 
outcomes of maternal obesity over the lifespan have not been quantified, and the molecular 
changes induced by maternal obesity remain poorly characterized. We hypothesize that ma-
ternal insulin resistance and reduced placental glucocorticoid catabolism, leading to oxidative 
stress, may damage the DNA, either in its structure (telomere shortening) or in its function 
(via epigenetic changes), resulting in altered gene expression/repair, disease during life, and 
pathological ageing. This review illustrates the background to the EU-FP7-HEALTH-DORIAN 
project.  © 2014 S. Karger GmbH, Freiburg 
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 Introduction 
 Obesity has reached epidemic proportions and is the main health as well as social concern 
in the developed world and, increasingly, in developing countries. In the EU, one third of 
women of reproductive age are overweight and 20% are obese. This prevalence is expected 
to almost double in the next decade  [1] . Maternal obesity is associated with adverse acute 
maternal and neonatal outcomes, and the long-term consequences of maternal obesity in 
pregnancy have large implications both for the mother and her offspring  [2–10] . However, 
the underlying mechanisms are largely unknown.
 Obesity is associated with a markedly elevated risk of type 2 diabetes (T2DM)  [8–10] . 
Overweight of the mother also increases the offspring’s predisposition to obesity and 
T2DM. Several mechanisms, not mutually exclusive, may explain the associations between 
exposure to obesity in utero and long-term metabolic disadvantages in the offspring, i.e., 
genetic and lifestyle factors as well as specific intrauterine effects. Epidemiological and 
clinical studies as well as experimental animal work have introduced the concept of Devel-
opmental Origins of Health and Disease. Prenatal environmental adversities may exert 
lifelong consequences by programming the offspring’s cells, tissues, organs, their structure 
and function. The evidence for early programming is strongest for cardiovascular disease 
(CVD) and T2DM. 
 One developmental pathway to obesity is the foetal over-nutrition pathway  [11] , reflecting 
the effects of hyperinsulinaemia and other factors during foetal life. This creates conditions 
for later pathophysiological effects of an obesogenic environment. Alterations in maternal 
lipid metabolism may also contribute to the over-nutrition pathway  [12] . Free fatty acids and 
triglycerides are elevated in mothers of obese neonates. Lipids play a key role in adipocyte 
differentiation; thus, increased transfer of free fatty acids might affect foetal adiposity by 
influencing the number, size or lipoprotein lipase activity of foetal fat cells. The adipoinsular 
axis is an endocrine feedback loop regulating hunger and fat storage through e.g., insulin and 
leptin. Hyperinsulinaemia (indicating a state of insulin resistance) and hyperleptinaemia are 
hallmarks of obesity. Cord blood leptin concentrations correlate positively with birth weight 
and adiposity. Excessive substrate exposure and insulin resistance (IR) may induce oxidative 
stress (OS) and damage to body organs.
 Chronic stress and the hyperactivation of the hypothalamic-pituitary-adrenal (HPA) axis 
is another common feature in obesity, and cortisol is a potent hormone affecting early devel-
opment.
 Also, epigenetic mechanisms acquired in early life have been suggested to have pheno-
typic consequences later in development through their role in transcriptional regulation with 
relevance to the developmental origins of diseases including obesity  [13, 14] . Changes in epi-
genomic patterns and gene expression are believed to be a key underlying mechanism, 
resulting in phenotypic differences between individuals that persist across the lifespan. The 
epigenome is particularly susceptible to alterations during gestation, because the DNA 
synthesis rate is high and the DNA methylation patterning required for normal tissue devel-
opment is established during this time. Epigenetic modifications in response to adversities 
may lead to metabolic imprinting of permanent alterations in genes involved in the regulation 
of energy homeostasis. 
 Despite the evidence that exposure to obesity in utero is associated with T2DM in the 
offspring, very little is known about how this exposure influences  metabolic abnormalities. 
T2DM is associated with an increased risk for CVD and premature death. The influence of 
maternal overweight and obesity on ageing-related outcomes has not been studied previ-
ously. Even less is known on whether or not it would be possible to influence these metabolic 
outcomes by lifestyle modification in adulthood.
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 This review is focussed on the evidence implicating IR, chronic hormonal stress, OS and 
their consequences on premature DNA ageing in the pathogenesis of foetal programming of 
cardio-metabolic disorders in obese mothers’ offspring ( fig. 1 ).
 Insulin Resistance, Maternal Obesity, and Foetal Programming 
 Obesity is typically associated with IR, leading to hyperinsulinaemia. In women, this trait 
seems to confer an increased risk for hypertension, central fat accumulation, inflammation 
and adverse pregnancy outcomes  [15] . Maternal hyperinsulinaemia is associated with 
increased gestational weight gain and weight retention postpartum  [16] . Human placental 
lactogen, which increases with advancing gestation, cytokines and elevated lipid concentra-
tions have been correlated with the longitudinal changes in insulin sensitivity in pregnant 
women  [17–19] . Visceral adiposity is commonly associated with the above health outcomes, 
and the mass of visceral fat increases during pregnancy in lean and to a greater extent in 
obese women.
 Animal studies have shown that the offspring of female mice with diet-induced obesity 
develop IR, hypertension  [20] , adiposity and hyperphagia. They weigh more at birth because 
of increased fat at the expenses of lean mass  [21] , consistent with observations in piglets born 
to obese mothers, in which IR and greater body fat are accompanied by a depleted skeletal 
muscle mass (relative sarcopenia, i.e., an additional feature of unhealthy ageing), caused by a 
paucity of muscle cells  [22] . In a rat study, Beck et al.  [23] tried to mimic changes in food 
consumption patterns observed in pregnant women. The offspring of mothers, fed a high-
carbohydrate diet, showed hyperglycaemia and hyperinsulinaemia during adulthood. Mura-
bayashi et al.  [24] demonstrated that maternal high-fat diet (mHFD) in mice causes 
 Fig. 1. The hypothesis illustrated 
in this figure emphasizes the early 
mutual interaction between co-
existing mechanisms that has to 
be tackled for a full understanding 
of the long-term consequences of 
maternal obesity. Specifically, IR, 
glucocorticoid overexposure, and 
OS may be involved in the modula-
tion of TL, DNA methylation as 
well as DNA oxidative and mito-
chondrial damage as markers and 
mediators of the premature age-
ing caused by maternal obesity, 
leading to chronic disease and un-
healthy ageing. This figure is pub-
lic at  www.dorian-fp7.eu (in the 
project flyer). 
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inﬂammatory changes in the adipose tissue of the offspring. In this study, foetal subcutaneous 
adipocytes of the offspring of high-fat-fed mice were signiﬁcantly larger than those of control 
animals, and their subcutaneous adipose tissue showed macrophage inﬁltration in the stromal 
area as well as elevated expression of genes for chemokines mediating macrophage and 
monocyte chemotaxis and low levels of GLUT-4 mRNA. Studies in sheep, fed an obesogenic 
diet, documented tissue-specific defects in the insulin signalling cascade in the foetal 
myocardium and an impaired response to workload stress in the heart  [25] . Furthermore, the 
hearts of offspring born to obese agouti mice dams showed an increased susceptibility to 
ischaemia-reperfusion injury  [26] . In a sheep model, Yan et al.  [27] evaluated the effects of 
maternal obesity on the skeletal muscle of the 22-month-old offspring. They observed a 
reduction in the phosphorylation of proteins involved in stimulating insulin signalling and an 
increase in the phosphorylation of proteins involved in attenuating insulin signalling in the 
offspring of mothers fed an obesogenic versus control diet. These findings were accompanied 
by higher intramuscular collagen and adipocyte infiltration as well as by an increase in fatty 
acid transporters. Signs of inflammation were also detected in the progeny of obese sheep 
compared to that of control sheep  [28] .
 In humans, a greater flow of nutrients to the placenta and foetus in obese women 
promoted placental overgrowth, inflammation and increased foetal somatic growth  [29] . IR 
in the mother predicted the size  [30] and the degree of IR in the foetus  [31] . The foetuses of 
obese mothers had a greater percentage of body fat and IR as well as higher cord leptin and 
interleukin-6 levels than foetuses of lean women. Moreover, strong positive correlations have 
been shown between foetal IR and maternal BMI, foetal adiposity or cord leptin. In obese 
women, maternal IR had the strongest correlation with neonatal adiposity which is also a risk 
factor for childhood obesity and longer-term metabolic dysfunction  [2, 32] . The maternal BMI 
before and during pregnancy as well as a high birth weight in the new-born were the strongest 
early predictors of adiposity in 2- to 4- and 9-year-old children and of the metabolic syndrome 
(MeS) in 6- to 11-year-old children  [3, 32, 33] . Maternal insulin sensitivity during pregnancy 
explained a considerable and additional proportion of the variance in birth weight and 
adiposity in the offspring  [34] .
 Most animal and human studies so far focused on the effects of maternal obesity on early 
metabolic abnormalities in the offspring. In a small study on minipigs, we introduced the use 
of positron emission tomography as a way to measure (repeatedly over time) organ-specific 
insulin sensitivity. Our results showed that mother and offspring had very similar metabolic 
features at the time of birth and lactation, but strong factors, such as sex and growth (rate of 
weight change), may come into play after weaning  [35] .
 Chronic Stress, Obesity and Foetal Programming 
 A large body of epidemiological evidence indicates a strong link between chronic stress, 
especially social stress, and metabolic disturbances  [36] . The term stress is commonly 
defined as a state of threatened homeostasis  [37] . A challenge by either intrinsic or extrinsic 
stressors to homeostasis induces specific response mechanisms, most prominently the 
sympathetic nervous system and the HPA axis, which result in a series of neural and endo-
crine adaptations known collectively as the stress response. While the adaptive response to 
acute stressors is advantageous for survival, periods of chronic stress or stressful life events 
may be maladaptive and have been associated with a variety of pathological conditions  [38–
42] . Specifically, chronic stress represents a major risk factor for the development of 
abdominal obesity and the MeS, i.e., a cluster of metabolic factors that increase the risk to 
develop CVD and T2DM  [42–44] . Animal models provide further evidence for an interaction 
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between the stress response and energy balance, such that exposure to stress mediates 
changes in feeding behaviour, caloric intake and body weight changes  [36, 42–45] . Despite 
both strong epidemiological and animal model associations between chronic stress exposure 
and metabolic disturbances, the molecular basis underlying this relationship remains largely 
unknown.
 Maternal obesity is an escalating health concern that increases the risk of complications 
during pregnancy and the risk of adverse foetal outcomes  [46] . Through foetal programming, 
the adverse effects of maternal obesity may extend far beyond any acute consequence and 
may elevate the risk of various pathologies later in life  [47] . In particular, evidence suggests 
that maternal obesity has a long-term impact on metabolism, including an increased risk of 
obesity and the MeS in adult offspring prenatally exposed to mHFD  [48–51] . 
 Beyond increased risk of metabolic disturbances, most notably IR, evidence shows 
adverse effects of mHFD on offspring’s brain development, affective behaviour and cognition 
 [52] . Specifically, animal studies have noted alterations in hippocampal and hypothalamic 
regions as well as in serotonergic, dopaminergic and opioid neurotransmitter systems, 
resulting in alterations of cognitive and affective behaviours in offspring born to obese 
mothers  [53–60] . To date, relatively little research has focused on the long-term effects of 
mHFD on the offspring’s stress response although the literature  demonstrated common 
regulatory neural pathways between the stress response and metabolic homeostasis systems 
 [61] . Nevertheless, nutritional status during gestation and lactation is recognized to have 
effects on the stress response. For example, a protein-restricted diet throughout gestation 
programs altered tissue-specific glucocorticoid action mediated by changes in expression 
profiles of glucocorticoid receptors (GR) and 11β-hydroxysteroid dehydrogenase type 2 
(11β-HSD2)  [62] . Furthermore, studies investigating prenatal stress, or glucocorticoid 
exposure, in rodents have revealed features associated with the MeS, namely hypertension 
and hyperglycaemia  [63–66] . 
 The limited number of studies that already have examined the effects of mHFD on the 
stress response, specifically the HPA axis function, demonstrated alterations in HPA axis 
responsiveness after an acute stressor in neonates and prepubertal rats exposed to mHFD 
 [67] . Moreover, it has been shown that the neonatal HPA axis is sensitive to metabolic signals, 
including glucose and ghrelin  [68] , suggesting that changes in the level of metabolic signals 
that result from changes in maternal diet may influence the development of the neonate’s 
HPA axis response. However, a comprehensive behavioural and endocrine characterization 
of the long-term impact of mHFD, combined with challenging conditions such as chronic 
stress, is still lacking. Accordingly, we propose to evaluate the long-term impact of mHFD and 
to study the interplay of metabolic disturbances and stress system dysfunction in the offspring 
under basal conditions as well as following adverse challenges.
 Chronic stress is not only a risk factor for the development of metabolic disturbances but 
also for affective disorders. Dysregulation of the HPA axis as well as heightened stress reac-
tivity are among the most consistent features in patients suffering from major depression 
(MD)  [69–71] . Moreover, a comorbidity between MD and obesity exists, whereby depressed 
patients show higher rates of general obesity and related diseases; likewise, patients diag-
nosed as obese show increased rates of affective disorders  [72–76] . Preliminary results 
indicate that antidepressants may not only be clinically effective in depression but may also 
have therapeutic effects in obesity-related disorders through changes in GR expression and 
subsequent restoration of the HPA axis activity  [77–79] . These observations suggest that 
there is a common mechanistic link in the pathophysiologies of MD and obesity. However, to 
date it is unclear to which extent maternal obesity can modulate the risk for affective disorders 
and how antidepressant treatment will affect the emotional but also the metabolic phenotype 
in the offspring.
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 Role of 11β-Hydroxysteroid Dehydrogenase Type 2 in Developmental Programming 
 The developing foetus is maintained in a low glucocorticoid environment, to protect 
against the potent effect of glucocorticoids that accelerate foetal organ maturation in a 
trade-off against overall growth. To maintain the glucocorticoid gradient between mother 
and foetus, physiological glucocorticoids are catabolized by foetal and placental 11β-HSD2, 
converting active glucocorticoids to the inactive 11-keto derivative. The hypothesis then 
developed that variations in foeto-placental 11β-HSD2 may underlie prenatal glucocor-
ticoid programming  [80] . The observation that placental 11β-HSD2 activity correlated 
directly with birth weight in rodent  [81] and in most human studies  [82–85] , suggests that 
normal variation in foetal exposure to maternal glucocorticoids has an impact on foetal 
growth. 
 Furthermore, inhibition, genetic deficiency or by-pass (using poor-substrate steroids 
such as dexamethasone or betamethasone) of placental 11β-HSD2 in model species and 
humans was associated with reduced pregnancy duration, lower birth weight and programmed 
outcomes, cardio-metabolic as well as psychiatric, in the offspring  [81, 86–99] . Humans who 
were homozygous / compound heterozygous for deleterious mutations in  HSD11B2 had low 
birth weight compared with their largely heterozygous siblings  [86, 88, 100] . Similarly, 
Hsd11b2–/– mice had lower full-term weight  [92] .
 Furthermore, Finnish women who voluntarily ate larger amounts of liquorice-containing 
foodstuffs (liquorice contains an inhibitor of 11β-HSD) in pregnancy had shorter gestations, 
and their children showed poorer cognitive function and affective disturbances (notably 
markedly increased rates of attention deficit hyperactivity disorder) coupled with modest 
HPA axis hyperactivity  [101, 102] . The central programming of the brain and behaviour by 
glucocorticoids was replicated in animal models. Hence, maternal administration of dexa-
methasone or prenatal stress produced offspring that appeared to be more anxious as adults. 
Thus, late gestational dexamethasone exposure in rats impaired the offspring’s ‘coping’ 
behaviours in aversive situations later in life as exemplified by reduced exploration in the 
open field test and the elevated plus maze  [103] . Such an increase in anxiety-like behaviour 
was evident as early as in postnatal week 10 in rats prenatally exposed to dexamethasone 
 [104] . Moreover, 11β-HSD2 appears important in these events since treatment of pregnant 
rats with an 11β-HSD inhibitor just as gene deletion in mice produced offspring with enhanced 
anxiety-related behaviours  [90, 92] . 
 The mechanisms of these programmed effects are tissue-specific and involve glucocor-
ticoid-driven changes in target organ structure, gene expression and gene function. Epigenetic 
processes maintaining such effects have been advocated  [64, 90, 93, 95, 103, 105–110] . 
Indeed, the key genes involved in HPA axis activity, i.e., those coding for corticotropin-
releasing hormone and arginine vasopressin, GR and 11β-HSD2 itself, showed altered 
expression in models of programming, and the promoters of all three encoding genes showed 
persisting changes in methylation in response to early-life environmental challenges  [111–
114] . Methylation of DNA during gestation is in part determined by the availability of methyl 
donors  [115] , and placental 11β-HSD2 impacts on placental transport of key methyl donors 
 [116], implying a possible additional role in determining foetal epigenetic status.
 A core issue in foetal programming is to determine the locus of action of environmental 
challenges, specifically distinguishing indirect effects upon the mother from more direct 
impacts upon the placenta and/or the foetus. This has been achieved by crossing male and 
female mice heterozygous for a null allele of  Hsd11b2 . This results in wild-type, heterozygous 
and homozygous null  Hsd11b2 offspring in the same dam. Since placental 11β-HSD2 in the 
labyrinth zone is derived from the foetal genotype, this design afforded a clear differentiation 
of foeto-placental from maternal effects. In this model, birth weight and offspring affective 
behaviour followed the foeto-placental genotype  [92] , excluding maternal effects from this 
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manipulation of 11β-HSD2. Of course, the  Hsd11b2–/– offspring also lacked the enzyme in 
kidney and were thus hypertensive and hypokalaemic  [117], which complicated the 
assessment of cardio-metabolic programming. Studies of tissue-specific knockout of 
11β-HSD2 in foetal organs will allow distinction of the relative importance of the placental 
and individual foetal tissue ‘barriers’ to glucocorticoids. 
 An additional and important level of impact of 11β-HSD2 is on placental function per se. 
In the heterozygous cross model, placentas completely lacking 11β-HSD2 showed restricted 
growth in late gestation, even before foetal growth was retarded  [98] . In late mid-gestation, 
placental amino acid transport to  Hsd11b2–/– offspring was increased, suggesting compen-
sation for placental dysfunction. However, in the near term, the  Hsd11b2–/– placenta was 
failing with markedly reduced placental glucose transport and decreased glucose transporter 
3 expression. The late-gestation  Hsd11b2–/– placenta lacked the normal increase in density 
of foetally derived blood vessels and showed reduced expression of the key angiogenic factor 
vascular endothelial growth factor (normally down-regulated by glucocorticoids  [118] ) and 
a key angiogenic transcription factor, i.e., peroxisomal proliferator-activated receptor gamma. 
Glucocorticoids and 11β-HSD inhibitors advanced apoptosis in the term placenta  [119] . Such 
underweight, under-vascularized, and under-functioning placentas are poorly equipped to 
supply the rapidly growing and maturing near-term foetus.
 Relationship between Glucocorticoid and Nutritional Programming 
 Intriguingly, 11β-HSD2 itself appeared to be a target for foetal programming, with 
persisting reductions in renal 11β-HSD2 mRNA levels and increased mineralocorticoid 
activity of glucocorticoids in sheep exposed to under-nutrition  [120] . In humans, children 
exposed to the horrors of the Nazi Holocaust showed reduced renal 11β-HSD2 activity in old 
age, with the greatest effect seen in those youngest at traumatization  [121] . These data 
suggest that 11β-HSD2 is a programming target in humans, possibly to maximize renal 
sodium retention in what may be anticipated to be a starvation-associated sodium-poor 
environment. 
 Low protein diet in pregnancy caused an increase in maternal and foetal glucocorticoid 
levels  [122–123] , together with a decrease in placental 11β-HSD2 activity  [62, 124, 125] . 
Conversely, exposure to dexamethasone during pregnancy decreased maternal food intake 
 [126] and reduced maternal weight gain  [91] . These results suggest that there are common 
mechanisms underpinning both nutritional and glucocorticoid developmental programming. 
Feeding low-protein diet to the pregnant dams of heterozygous  Hsd11b2  crosses showed that, 
although both maternal undernutrition and 11β-HSD2 deficiency reduced foetal growth and 
both involved foeto-placental overexposure to glucocorticoids, the mechanisms were distinct. 
Thus, 11β-HSD2 insufficiency increased foeto-placental exposure to maternal glucocorti-
coids, whereas low-protein diet activated the foetal HPA axis to produce increased foetal 
glucocorticoid levels  [127] . Consistent with this, prenatal under-nutrition increased levels of 
adrenal steroidogenic enzymes at birth  [128] . 
 Studying a unique human population in Motherwell, Scotland, who were advised by their 
obstetrician to eat 0.45 kg of red meat a day and to avoid carbohydrate-rich food during preg-
nancy, revealed that this abnormal diet programmed high blood pressure  [129] , high cortisol 
levels  [130], and heightened HPA axis responses to stress  [131] . These programmed pheno-
types may be underpinned by the associated change in methylation patterns of 11β-HSD2-, 
GR-, and insulin-like growth factor 2-encoding genes  [132] .
 With the obesity epidemic producing more babies born to obese mothers, it is of concern 
that there is also adverse programming of cardio-metabolic outcomes in these offspring  [133, 
134], and it now becomes crucial to determine if 11β-HSD2 plays a role in mediating these 
effects. 
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 Oxidative Stress 
 Life expectancy has greatly increased in the last century although, in most industrialized 
countries, this has been paralleled by an increased incidence of neurodegenerative disorders 
in addition to cardiovascular and metabolic pathologies. The p66Shc gene has emerged as a 
novel gerontogene affecting health throughout life and during ageing. In the last decade, 
studies on  p66Shc knock-out mice have indicated that this gene is a crucial regulator of 
reactive oxygen species levels and is involved in age-related dysfunctions. p66Shc–/– mice 
indeed showed a healthy phenotype characterized by greater brain and behavioural plasticity 
in addition to reduced OS, fat accumulation and incidence of metabolic- as well as cardiovas-
cular pathologies  [135–141] . Studies performed in a semi-naturalistic setting, involving 
exposure to low temperatures and food shortage, indicated that p66Shc has been conserved 
through evolution because of its role as ‘thrifty gene’ in energy metabolism. This feature, 
which increases the probability for survival in harsh natural conditions, can be deleterious 
when food is constantly available, as in westernized lifestyles, leading to fat accumulation and 
thus predisposing to metabolic, CVD and accelerating brain ageing. 
 The p66Shc gene appears to be one of the converging points linking OS, metabolism, and 
the genetics of ageing. So far, a number of animal models, developed to study the ageing 
process, suggested a relationship between changes in general metabolism or in the cellular 
redox milieu and longevity  [142–148] . P66Shc–/– mice are characterized by reduced OS, 
elevated resistance to high-fat-induced obesity, and, more importantly, are long-lived, repre-
senting a unique opportunity to study the ageing process in vivo, and thus the relationship 
between longevity and health  [135–141] . Being at the crossroad of signalling pathways 
involved in both central and peripheral stress responses and in the regulation of energy 
homeostasis, p66Shc is a good candidate molecule to address the mechanisms underlying 
healthy ageing and to be targeted for the development of novel pharmacological tools for the 
prevention or cure of age-related pathologies. In humans, ageing largely contributes to meta-
bolic decline and to the aetiology of related pathological conditions such as T2DM, CVD and 
stroke  [149] . IR and abdominal obesity, often observed in older adults, are main components 
of the MeS, a pathological condition characterized by multi-organ morbidity  [150, 151] . The 
increased secretion of pro-inflammatory cytokines often observed during ageing interferes 
with insulin action, and these cytokines derive from both the age-associated accrual of visceral 
fat and increasing numbers of senescent cells  [152] . However, a growing body of evidence 
shows that the incidence of obesity, and the often associated MeS, is increasing in the young 
population, especially in western countries  [153] . These morbid conditions are accompanied 
by a whole metabolic unbalance with high levels of OS and inflammation in addition to shorter 
telomeres (that correlate with increasing BMI), overall resembling a form of precocious 
ageing  [154] . Furthermore, patients with MeS are often characterized by a higher incidence 
of mood and cognitive dysfunctions than the general age-matched population that, in turn, 
emerge as significant risk factors for aggravation of MeS and the related health outcomes, 
particularly CVD and type T2DM  [155–160] . Thus, overall, alterations in metabolism and 
body fat distribution certainly play a role in a vicious cycle that can precipitate the ageing 
process and the onset of diseases  [149] . The mechanisms that account for these phenomena 
are incompletely understood; however, longevity genes might be involved. Very recently, 
Fadini et al.  [154] proposed SIRT1, p66Shc and the mammalian TOR (mTOR) ⁄ RSK ⁄ AMPK 
pathways to play a role in this clinical context because they integrate nutrient bioavailability, 
OS as well as metabolism and because biological plausibility supports their reciprocal inter-
connections. 
 Given the obesity epidemic in western countries, a main research question is the role of 
maternal obesity in setting up a state of individual susceptibility to metabolic and neurode-
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generative disorders at adulthood. The data available for humans indicate that the foeti of 
obese mothers are exposed to higher levels of insulin. Overall, gestational IR and obesity 
favour hyperglycaemia, relative fat excess and sarcopenia as well as greater birth weight and 
higher blood pressure in the offspring which are recognized risk factors for CVD, T2DM and 
cognitive impairment. It is possible to hypothesize that reduced exposure to OS from early 
development throughout life might protect the p66Shc–/– mutants from the negative effects 
of free radicals, resulting in a more efficient homeostatic control and better abilities to cope 
with changes in the internal milieu, attenuating the effects of ageing on the nervous system 
and causing an improved overall health status. Those mice which showed reduced OS, were 
lean and resistant to obesity, atherosclerosis, ischaemic injury, diabetes, neurodegeneration 
as well as cancer, and showed increased longevity, were an ideal model to study the mecha-
nistic hypothesis underlying the relationship between maternal obesity, offspring metab-
olism, OS and longevity.
 DNA Expression and Structure and Its Alterations 
 Epigenetic Regulation (Influences) 
 In the last decade, epigenetic changes in the human genome have been recognized as a 
very important determinant of cellular senescence and age-related diseases  [161, 162] . 
Epigenetics refers to modifications of the genome without change in the primary DNA 
sequence that can be inherited both mitotically and meiotically. 
 The most widely studied and best characterized epigenetic mark is DNA methylation: it 
consists of a catalytic addition to the fifth carbon position of cytosine nucleotides of a methyl 
group throughout the genome within CpG dinucleotides, the so-called CpG islands. DNA meth-
yltransferases (DNMTs) enzymes (DNMT1, DNMT3A and DNMT3B) are responsible for meth-
ylation pattern acquisition during gametogenesis, embryogenesis and somatic tissue devel-
opment.
 Most of the CpG islands are located in the promoter region and the first exon of approxi-
mately half of all human protein-coding genes, and remain free of methylation. In the normal 
cell, only imprinted genes, genes whose expression is restricted to male or female germ line 
and tissue-specific genes are silenced by methylation mechanisms.
 Promoter hypermethylation generally results in a decreased gene transcription or abol-
ishes gene expression. Changes in methylation of CpG islands correlate with altered gene 
expression and can contribute to a disease phenotype. 
 Ageing and age-related diseases are generally characterized by genome-wide hypometh-
ylation and promoter-specific hypermethylation  [161, 162] .
 Notably, modifications are reversible and are, therefore, a potential target for therapeutic 
intervention. In fact, numerous drugs that specifically target DNMTs are currently tested in 
ongoing phase II–III clinical trials for cancer therapy  [163] .
 Because DNA methylation patterns are largely established in utero, nutritional insult 
during a critical period of gestation may alter the epigenetic state of the foetal genome, 
inducing stable changes in gene expression that may be sustained throughout the lifespan of 
an individual  [164] .
 Indeed, data from animal models suggest that maternal nutrition status can influence 
metabolic phenotypes through epigenetic changes  [165–167] . Accordingly, a recent study 
showed that methylation status of CpGs in the promoters of candidate genes in DNA extracted 
from umbilical cord tissue obtained at birth were related to adiposity in later childhood and 
to information on the mother’s diet during pregnancy  [168] . These data strongly support that 
epigenetic changes occurring during gestation, as mediated by the maternal diet, have a 
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prolonged impact on adiposity and related metabolic phenotypes which in turn would be 
expected to influence the risk for diabetes and its complications.
 However, the understanding of the mechanism by which maternal nutrition can modify 
the epigenome requires further research. Specifically, we hypothesize that other combina-
tions of gene promoters may have a central position in epigenetic control of maternal obesity 
and age-dependent methylation. Promoter-specific DNA methylation in selected candidate 
genes (e.g., cell cycle regulation genes) can provide evidence for the influence of maternal diet 
during gestation on foetal gene expression as well as their roles in the regulation of cellular 
senescence and premature ageing. In addition, as outlined above, placental 11β-HSD2 impacts 
on placental transport of key methyl donors, and the key genes as well as gene promoters 
involved in HPA axis activity altered expression in models of programming. Therefore, we 
propose to examine the synergy between over-nutrition and HPA axis dysregulation in estab-
lishing epigenetic changes during foetal programming in offspring of obese mothers. 
Furthermore, it will be of great interest to analyze whether lifestyle changes might reverse 
promoter methylation levels.
 The use of now available next-generation sequencing platforms can also help to identify 
genes susceptible to epigenetic modifications in response to nutritional exposure in utero.
 Methods to Study the Epigenome 
 An increasing number of human diseases has be shown to be associated with epigenetic 
alterations  [169] . Therefore, computational epigenetics has become an important branch of 
computational biology. Computational epigenetics is concerned with the development of 
bioinformatics methods to complement experimental epigenetics research, and, as such, has 
developed a range of bioinformatics methods for the analysis of second-generation sequencing 
data from epigenetic studies  [170] . 
 Epigenetic alterations that are being studied include cytosine methylation and chro-
matin modifications. Chromatin modifications are usually examined using techniques 
such as immunoprecipitation of chromatin followed by sequencing of the corresponding 
DNA fragments. DNA methylation can be studied using bisulphite sequencing of specific 
regions or, indeed, of the whole human genome  [171] . While whole-genome bisulphite 
DNA sequencing offers single-nucleotide resolution of DNA methylation, it is currently 
prohibitively expensive for use on a large scale. A solution for this is the affinity-based 
enrichment of methylated DNA, using methyl-CpG-binding domain (MBD) proteins 
followed by next-generation sequencing (MBD-seq)  [172] . The advantage of the selective 
enrichment of methylated DNA is that it allows the routine analysis of the methylation 
states of large genomes, such as those of human and mouse. We propose to enrich the 
methylated fraction of the genomic DNA of the respective human and mouse sample by 
affinity-based enrichment using MBD-seq by the Illumina Genome Analyzer platform in 
order to study the differential methylation in target study models. A pipeline will be 
developed for aligning sequence reads to the reference genome, using existing next-gener-
ation sequencing analysis tools such as Novoalign ( www.novocraft.com ) or bwa  [173] for 
the Illumina platform. Subsequently, the data will be analyzed using specific tools for the 
analysis of methylated DNA sequencing data, such as MeQA  [174] . Loci exhibiting differ-
ential methylation patterns will be compared to their syntenic regions in human and 
analyzed with motif-finding software, such as Meme  [175] , in order to search for conserved 
patterns in these loci. Since alternative splicing has been linked to predisposition to obesity 
 [176] , alternative transcripts of genes associated with differentially methylated loci will 
be studied, and their conservation will be explored in the human genome. By selecting 
specific biomarkers, we will develop an automated sequence-based method for the early 
diagnosis of disease susceptibility.
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 Oxidative DNA Damage to Telomeres and Chromosomes 
 Telomeres are DNA-protein complexes at the ends of chromosomes, composed of tandem 
(5 ′ -(TTAGGG)n-3 ′ ) repeats, and ranging between a few and 15 kb in length. Their main 
function is to protect chromosome integrity and stability from nucleolytic degradation, 
unnecessary recombination and interchromosomal fusion. It is now well established that 
telomeres shorten with every cell cycle because DNA polymerase is unable to fully replicate 
the 3 ′ -end of the DNA strand. Thus, telomere shortening, ranging between 30 and 150 base 
pairs with each cell division, is physiologically associated with ageing. Telomerase is a ribo-
nucleoprotein reverse transcriptase that maintains telomere length (TL) by adding telomeric 
DNA to existing telomeres. While it is well expressed and active in germ cells, telomerase 
abundance decreases with gestational age and differentiation progress; eventually its 
expression becomes poor in somatic cells of children and adults. 
 When TL reaches a critical limit, the cell undergoes senescence or apoptosis, or oncogenic 
transformation. In addition to its natural and age-related rate, telomere shortening may be 
accelerated by additional factors such as epigenetic regulation, OS and many others which are 
currently under investigation.
 Excessive or accelerated telomere shortening affects health and lifespan at multiple 
levels. In adults, TL inversely correlated with age, hypertension, coronary heart disease, 
T2DM, IR, cancer and mortality rate. Moreover, neurologic/psychiatric conditions such as 
MD, schizophrenia, migraine, mild cognitive impairment and Alzheimer disease are also asso-
ciated with shorter telomeres  [177] . 
 A growing body of evidence shows that telomere shortening rate can be increased by 
several lifestyle factors, including obesity, diet composition and psychosocial stress among 
the prominent ones.
 BMI has been shown to correlate with biomarkers of DNA damage independently of age 
 [178] , and shorter leucocyte telomeres have been found in obese women compared to a 
control group  [179] . Deregulation of adipokines, local and systemic OS, increased circulating 
oxidizing agents and lower levels of antioxidant enzymes, such as catalase and dismutase 
 [180] , are likely to represent the main mechanisms underlying accelerated telomere short-
ening and cell senescence in obese subjects. Shorter telomeres were found in hypertrophic 
adipocytes of both visceral and subcutaneous fat from obese and T2DM patients when 
compared to control subjects and were shown to be directly associated with cell size and lipid 
peroxidation and inversely related with adiponectin levels  [181] . Although the association 
between obesity and accelerated telomere shortening is well accepted, the direction of the 
relationship is still controversial. A longitudinal study in a cohort of 2,721 elderly subjects 
found that shortening of TL was associated with adiposity. However, the correlation was 
significant with some obesity-related parameters (i.e., % body fat, subcutaneous fat and 
leptin) but not with others (i.e., BMI and visceral fat), which leaves the mutual interplay 
between obesity and TL still uncertain  [182] .
 Some authors showed that in addition to excessive food intake and overweight/obesity, 
dietary composition affects the rate of telomere shortening. In particular, TL was positively 
associated with the intake of fibre and antioxidants, and negatively associated with polyun-
saturated fatty acids as well as protein  [183] . In rat models, diet restriction and protein 
restriction led to reduced growth rate, reduced DNA damage, reduced telomere shortening 
and increased lifespan  [184] .
 Psychosocial stress  was associated with increased release of glucocorticoid hormones, 
which have been shown to increase reactive oxygen species by reducing antioxidant protein 
levels, thus further enhancing OS-dependent telomere shortening. Shorter telomeres and 
reduced telomerase activity have been found in women experiencing stress in their daily life 
compared to controls  [185] .
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 Although only few longitudinal studies investigating the association between TL and 
obesity exist, it seems that weight gain, rather than the obese status per se, is a more important 
factor affecting telomere shortening rates  [186] . This observation, together with the epidemic 
of overweight and obesity in children, urges the need to understand if early development may 
be affected by premature ageing due to nutritional and inflammatory features during 
childhood, including the pre/post-natal periods. In a case control study on 793 children aged 
2–17 years, leucocyte telomeres were  ∼ 24% shorter in obese than in non-obese children 
 [186] , with no difference between males and females. Other authors did not find any  [187] or 
only found sex-related differences  [188] between obese and lean subjects.
 Growing evidence from epidemiological, clinical and molecular studies suggests that 
intrauterine life is critical in the developmental programming of health in adult life, especially 
with regard to chronic conditions that are associated with systemic inflammation and OS. 
However, the mechanisms and pathways accounting for prenatal-dependent postnatal 
susceptibility to diseases are still unrevealed. Telomere shortening / deficient repair capacity 
may be sensitive to nutritional, hormonal or psychological stresses during the intrauterine 
period.
 Only few and recent papers have addressed TL in the foeto-placenta unit and cord blood 
to provide evidence of intrauterine programming towards a premature senescent phenotype 
in the infant  [189] . Inter-individual variation in the initial length of telomeres was remarkable, 
in spite of its high heritability. Studies in animal models  [184, 190–192]  have  shown that 
adverse conditions during intrauterine life, as well as prenatal cortisol administration in 
chickens  [192] , were associated with increased telomere shortening and decreased telom-
erase activity. Other studies in humans found that adverse conditions during pregnancy, such 
as foetal growth restriction, diabetes, preeclampsia and exposure to psychosocial stress, 
were associated with accelerated telomere shortening in the offspring  [193–197] . Increased 
telomerase activity was found in the cord blood obtained from type 1 diabetic women, but 
not in the cord blood of women with T2DM or gestational diabetes; however, the groups did 
not differ with regard to TL. Telomerase activity in the foeto-placenta unit might have been 
enhanced to counterbalance the pro-inflammatory and pro-oxidant environment that char-
acterizes diabetes and might indicate a potentially dangerous intrauterine environment  [192, 
197] .
 Beside telomere shortening, mutations and aberrations of mitochondrial DNA (mtDNA) 
are ageing-related hallmarks. Shorter telomeres, decreased mtDNA content, increased OS and 
hypoadiponectinaemia were found in T2DM patients  [181] . A model integrating telomere 
biology and mitochondrial function has been suggested by several studies. In fact, a telomere-
p53-mitochondrion axis may account for many processes shown to be important in patho-
physiological ageing  [198] . According to this model, telomere shortening is the driving force 
that generates mitochondrial dysfunction via activation of the transcription factor p53. Then, 
mitochondrial dysfunction leads to impaired metabolic- as well as energetic homeostasis and 
increased OS which sustain a feed-forward cycle of further DNA damage and mitochondrial 
dysfunction.
 Due to its proximity to the site of generation of reactive oxygen species and free radicals, 
mtDNA is highly susceptible to mutations. In tissues with a high metabolic rate and low prolif-
erative index (e.g., brain and heart), mutations accumulate faster than in other tissues due to 
a greater potential exposure to OS. A specific deletion of 4,977 base pairs, called the ‘common 
deletion’, has been detected with high frequency in tissues of adult subjects, but not in foetal 
and young tissues. Mitochondrial DNA 4977 bp deletion (mtDNA 4977 ) accumulated with age 
in clinically normal hearts as a consequence of the high metabolic rate of cardiomyocytes. 
Higher levels of mtDNA 4977 were found in cardiac-muscle specimens of patients with atrial 
fibrillation  [199] or suffering from coronary atherosclerotic heart disease  [200] . Higher 
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mtDNA 4977 levels were also detected in blood cells of coronary artery disease patients, inde-
pendently of age and sex. However, the amount of mtDNA 4977 neither correlated with athero-
sclerotic risk factors nor clinical parameters  [201] . Heritability of specific mitochondrial dele-
tions and the effect of maternal mtDNA alterations on the foeto-placenta unit have not been 
investigated yet. Nevertheless, the study of frequency of mtDNA ‘common deletion’ in condi-
tions potentially characterized by variable levels of systemic inflammation and OS along with 
altered metabolic homeostasis (i.e., obesity, IR, diabetes and the resulting intrauterine envi-
ronments) may be crucial to tackle in the developmental phase of life.
 Operationalization of Work in DORIAN 
 Figure 2 is the pert diagram of DORIAN, illustrating the interconnection between six 
work packages.
 Work package 1 (WP1) will address the long-, medium- and short-term effects of maternal 
obesity. The former will be studied in the Helsinki Birth Cohort Studies (HBCS) and the Arvo 
Ylppö Longitudinal Study (AYLS). HBCS-I and HBCS-II include individuals born 1924–1944, 
allowing to examine the effects of maternal obesity on ageing and the occurrence of chronic 
 Fig. 2. DORIAN integrates human clinical projects with research focussing upon basic mechanisms. It com-
prises four research work packages (WPs). There are two additional WPs: WP5 is dedicated to dissemination 
and WP6 to management. This figure is public at  www.dorian-fp7.eu . 
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non-communicable diseases through the lifespan in humans. AYLS includes young adults, 
followed up from birth, in whom the effects of maternal obesity on early risk determinants 
will be sought. Finally, WP1 includes investigations in pregnant mothers and their offspring 
at birth, enabling to dissect direct effects of the uterine environment from post-natal modu-
lators.
 Work package 2 (WP2) will explore the effects of maternal obesity in rodents which are 
suited to examine specific mechanisms and outcomes over the entire lifespan. In particular, 
the consequences of maternal IR will be explored in models that are prone to develop obesity 
and IR upon high-fat feeding. The consequences of hormonal stress will be examined in 
animals that are knocked-out for the placental degrading enzyme 11β-HSD2. The modulating 
actions of OS will be investigated in the p66 knock-out mouse model. Then, the findings of 
WP2 will be intertwined with those of WP1, in which biomarkers reflective of these pathways 
are measured in neonates, young adult, and elderly humans born to obese and lean mothers.
 Work package 3 (WP3) will receive biological samples from WP1 and WP2 to investigate 
genotoxicity, focusing on the shortening of telomeres that are reflective of DNA ageing and 
oxidative damage, and on epigenetic changes at birth by using a genome-wide approach (as 
described above) or a targeted (candidate gene) approach, looking at specific genes that are 
known to be associated with CVD or metabolic diseases.
 Work package 4 (WP4) will address prevention and reversibility of the effects of maternal 
obesity by using animal or human models as appropriate, and tools like PET and MR imaging 
to detect longitudinal changes in vivo at the specific tissue level (skeletal muscle, liver, heart, 
adipose tissue and brain) and in target molecular pathways (glucose and lipid metabolism, 
IR). Interventions will primarily be concerned with lifestyle changes, but drugs with known 
and selective effects on the processes of interest may also be used in rodents.
 Work package 5 (WP5) will be concerned with dissemination which is an important 
objective of the project, addressing the scientific community, primarily via publications and 
congresses and the stakeholders via dedicated workshops with the industry and policy 
makers. Means to transfer the information to the public, especially to reach mothers and 
families, have been carefully considered in the selection of DORIAN partners and in the design 
of the communication strategy. Importantly, we believe that dissemination is a two-way 
process in which we will use tools and create occasions to listen and learn from citizens and 
patients, providing their insight on what hold them from succeeding in good nutritional and 
lifestyle choices. We will learn from the experience of those who have participated in more 
successful campaigns against unhealthy habits, for example cigarette smoking.
 Work package 6 (WP6) will provide solid tools and qualified partners to monitor the 
progress of the project and of its dissemination in order to ensure a continuous exchange 
between partners and the timely delivery of reports and outcomes.
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